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Abstract 
 
Objectives: This study examined the child, parent, and service factors associated with 
polypharmacy in adolescents and young adults with ASD. Methods: As part of an online 
survey examining health service utilization patterns among individuals with ASD, parents 
provided demographic and clinical information pertaining to their child. This included 
information on current medication use, as well as information on clinical services 
received, clinical history, and parent wellbeing. Analyses examined the bivariate 
association between individual child, parent, and service variables and polypharmacy. 
Variables significantly associated with polypharmacy were included in a multiple 
variable logistic regression. Results: Of the 363 participants sampled, approximately one 
quarter were receiving two or more psychotropic drugs concurrently. The child’s 
psychiatric co-morbidity, history of hurting others, therapy use, and parent burden were 
predictors of polypharmacy. Conclusion: Adolescents and young adults with ASD are a 
highly medicated population with multiple factors associated with psychotropic 
polypharmacy. While there may be circumstances where polypharmacy is necessary, a 
richer understanding of what predicts polypharmacy may lead to targeted interventions to 
better support these individuals and their families.   
Findings also highlight the need to support families of children with ASD prescribed 
multiple psychotropic medications.   
Key words:  autism spectrum disorder; polypharmacy; psychotropic medication; 
adolescents; young adults 
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Child, parent, and service predictors of psychotropic polypharmacy among adolescents 
and young adults with autism spectrum disorders 
Individuals with an autism spectrum disorder (ASD) are frequently prescribed 
psychotropic medications (Chen et al. 2011; Coury et al. 2012; Hsia et al. 2013; 
Langworthy-Lam et al. 2002; Logan et al. 2012; Mandell et al. 2008; Memari et al. 2012; 
Rosenberg et al. 2010; Schubart et al. 2012; Spencer et al. 2013), with as many as half 
taking two or more psychotropic drugs in adulthood (Esbensen et al. 2009; Lake et al. 
2012). There are clearly circumstances where psychotropic medication use is warranted 
and necessary in this population, but its use is associated with a number of adverse effects 
including weight gain, sedation, irritability, tardive dyskinesia, and gastrointestinal 
problems (Matson & Hess 2011; McCracken 2005; Myers 2007). Long-term secondary 
effects include diabetes, cardiovascular disease, and hyperlipidemia (Posey et al. 2008; 
Stigler et al. 2004). These effects and the risk of adverse drug reactions and drug-drug 
interactions are heightened when multiple psychotropic medications are used (Lunsky 
and Elserafi 2012; Perkins and Berkman 2012; Schall 2002). Psychotropic polypharmacy, 
defined in this study as the concurrent use of two or more psychotropic medications in 
the same individual, while sometimes clinically indicated, is a recognized concern for 
individuals with ASD due to increased sensitivity to side effects and difficulties 
communicating and reporting their internal experience (Schall 2002).  
To date, the majority of studies on psychotropic polypharmacy in individuals with 
ASD have been descriptive in nature (Aman et al. 2003; Aman et al. 2005; Khanna et al. 
2012; Langworthy-Lam et al.  2002; Oswald and Sonenklar 2007; Tsakanikos et al. 2007; 
Witwer and Lecavalier 2005), with very few examining the factors associated with the 
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use of multiple psychotropic medications. Only four studies of children with ASD (Coury 
et al. 2012, Logan et al. 2012, Memari et al. 2012, Spencer et al. 2013) have examined 
factors associated with psychotropic polypharmacy, which have primarily focused on 
child demographic and clinical characteristics. Results of a large US study of 2,853 
children and adolescents with ASD identified that greater age, Caucasian race, and non-
Hispanic/Latino ethnicity were associated with the use of multiple psychotropic 
medications (Coury et al. 2012), along with gastrointestinal and sleep problems. In 
another large US study of 33, 565 children with ASD, older children, those who had a 
psychiatric visit, those with co-occurring conditions, Hispanic children and those living 
in southern regions, had higher odds of polypharmacy (Spencer et al. 2013). Although 
age is positively related to psychotropic polypharmacy in youth with ASD (Coury et al. 
2012, Logan et al. 2012, Memari et al. 2012, Spencer et al. 2013), only two studies have 
examined factors associated with psychotropic polypharmacy specifically among 
adolescents and adults with ASD. Findings from these studies suggest that greater age 
(Esbensen et al. 2009) and aggressive behaviour (Lake et al. 2012) predict the use of 
multiple psychotropic medications.  
There may be other contributors to psychotropic polypharmacy, which are not 
associated with the individual with ASD’s demographic or clinical presentation, but such 
variables have not been well studied. Utilization of non-pharmacological services (i.e., 
therapy, counseling, respite) and participation in structured daily activities (e.g., school, 
employment), may be important service variables to consider. One might expect that 
individuals who are unable to pay for medications would be less likely to use multiple 
psychotropic medications (Coury et al. 2012, Rosenberg et al. 2010), but the relationship 
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between psychotropic polypharmacy and availability and affordability of other types of 
services has not been studied. Parent circumstance may also play a role in prescription 
patterns. Research suggests that parents of children with ASD face significant caregiving 
burden (Cadman et al. 2009; Kring et al. 2008; Lin 2010), and that when families are in 
crisis they, and healthcare providers, may turn to medication as a solution (Mackintosh et 
al. 2012; Weiss et al. 2009). There are a number of possible parent factors that could 
contribute to this decision, including parent demographic variables (e.g., marital status, 
age, education) and parent psychological functioning (e.g., burden, crisis). Only two 
studies examined the relationship between polypharmacy and parent factors. In the first 
study, no association was observed between polypharmacy and poverty level, parent 
education or marital status (Memari et al., 2013). In the second study, household income, 
overall, was also mostly unrelated to polypharmacy (Spencer et al., 2013), but, no studies 
have considered the impact of other parent factors on psychotropic polypharmacy. 
While there are ample data suggesting that psychotropic polypharmacy is a 
concern among individuals with ASD, our current understanding of what leads to its 
occurrence is based on an examination of limited variables. Most of the literature to date 
has examined the relationship between psychotropic polypharmacy and child variables 
such as demographic and clinical symptoms, with less emphasis on other important 
potential drivers like service and parent variables. Further, most studies tend to focus on 
children (e.g., Coury et al. 2012; Spencer et al. 2013) even though psychotropic 
polypharmacy is more common in older youth and adults. There is a critical need to study 
older youth and young adults because of difficulties encountered in the transition from 
adolescence to adulthood when changes to residence, education, and employment may 
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occur. Given our knowledge that individuals with ASD tend to reside with their parents 
well into adulthood (Howlin and Moss 2012), and that adolescents and young adults’ 
with ASD have a high risk of psychotropic polypharmacy, it is important to have a more 
comprehensive understanding of the factors that contribute to its occurrence in this group. 
From a practice perspective, understanding more about the child, family, and service 
variables that increase the likelihood of psychotropic polypharmacy can improve patient-
centered care and treatment planning. Findings can also inform ways to support families 
of individuals with ASD prescribed multiple psychotropic medications.   
The current study addresses these gaps by examining the child, parent, and service 
variables associated with psychotropic polypharmacy in adolescents and young adults 
with ASD. Our study addresses the following objectives: 1) to determine the proportion 
of adolescents and adults taking two or more psychotropic medications 2) to identify the 
child, parent, and service variables associated with psychotropic polypharmacy.  
Methods 
The analyses reported here are based on data from a larger project examining health 
service utilization patterns among individuals with ASD. Parents of adolescents and 
young adults with ASD were recruited from educational, social service, recreational and 
mental health agencies and programs supporting people with ASD across Ontario.    
As part of an online survey, parents completed demographic and clinical measures 
about their child including; service use, comorbid medical and psychiatric conditions, 
medication use, risk behaviours, severity of ASD, history of previous hospitalizations, 
and use of other health services. Parents also completed measures related to their own 
demographics (age, education, gender) and personal wellbeing (e.g., burden, crisis). 
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Clinical and parent items were largely obtained from previously validated measures 
(Mackintosh et al. 2012; Xiong et al.2011), while demographic and utilization items were 
based on measures used in a previous study examining health service utilization patterns 
among individuals with developmental disabilities (Lunsky et al. 2012). Prior to 
launching the survey, measures were piloted among 10 families of adolescents and adults 
with ASD living in Ontario.  
Materials/Procedure 
 As part of an online survey examining health service utilization patterns among 
individuals with ASD, parents provided demographic and clinical information pertaining 
to their child. This included information on current medication use, as well as 
information on clinical services received, clinical history, and parent wellbeing. Only 
individuals who exceeded the recommended research cut off on the SCQ (≥12) (44), a 
validated parent report instrument of autism severity were included in these analyses. All 
parents provided informed written consent after being provided with a detailed 
description of the study. This study received ethics approval through the relevant 
institution’s institutional review board.   
Study Variables 
Child Variables 
 The following parent reported child variables were examined: age, gender, 
intellectual disability (ID), ASD diagnosis (autism, PDD-NOS, Asperger Syndrome), 
additional psychiatric diagnoses, history of hurting others, history of self-injury, and 
history of psychiatric admission. Individuals were classified as having ID if parents 
indicated that their child had a diagnosis of mild, moderate, severe, or profound ID.  
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Parent Variables 
Parent variables included age, marital status, education, presence of another child 
with ASD, parent burden, parent crisis, and family counseling. Parent burden was 
assessed using the 9-item Caregiving Burden Scale (Lawton et al. 2000), and parent crisis 
using the Brief Family Distress Scale (BFDS; Weiss and Lunsky 2009). The Caregiving 
Burden Scale measures caregiver’s appraisal of the physical, psychological, and social 
impact of caring for a child with ASD. Scores were categorized as low (<22), moderate 
(22–27) or high (>27) burden, as suggested by Pruncho and McMullen (2004). This 
measure has high internal consistency (Cronbach’s alpha=0.87) and acceptable stability 
(Lawton et al. 1989). Internal consistency of this measure in the current study was also 
high (0.92). The BFDS is a measure of perceived crisis in caregivers of individuals with 
ASD and consists of one item asking caregivers to rate on a scale of 1 to 10 where they 
and their family are currently in terms of crisis (Weiss and Lunsky 2011). Responses 
were dichotomized such that scores between 0 and 5 (i.e., no or moderate impairment) 
were classified as not currently in crisis and between 6 and 10 (i.e., marked impairment) 
as currently or approaching crisis. This scale has been shown to validly categorize 
families into groups based on their current crisis status (Weiss and Lunsky 2011). Family 
counseling was identified through parent report of family counseling services received in 
the previous two months. Parent education was dichotomized as high (college degree or 
higher) and low (high school or less).   
Service Variables 
 We examined service affordability, structured daily activity, therapy use, and 
respite use. To measure service affordability, parents were asked: “Can your family 
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afford to pay for services that you need in your community?” Responses were 
dichotomized as caregivers who could afford services vs. caregivers who could not. 
Structured daily activities included the individual with ASD’s typical participation in any 
of the following for at least some part of the day: school, work, volunteer, job training, or 
day program. Responses were dichotomized as yes structured daily activity and no 
structured daily activity. Therapy use was defined by receipt of any of the following 
services in the previous two months: behaviour therapy, individual counseling or group 
therapy. Respite use was also defined by use in the past two months.  
Outcome Variables 
Medications were categorized into the following 11 medication classes for 
standard use: a) Psychotropic medications: antidepressants, anxiolytics, atypical 
antipsychotics, typical antipsychotics, stimulants, mood stabilizers, antihypertensives 
(e.g., clonidine); and b) Non-psychotropic medications: anticonvulsants, medications for 
gastrointestinal issues, medications for sleep issues (e.g., melatonin, zoplicone), and other 
non-psychotropic medications. Only antihypertensive medications which had evidence 
for the treatment of hyperactivity, inattention, or impulsivity, such as clonidine or 
guanfacine, (Arnsten et al. 2007; Posey et al. 2004) were categorized as psychotropic 
medication, as was done by others (Aman et al. 2003; Langworthy-Lam et al. 2002; 
Logan et al. 2012). Similarly, the distinction between mood stabilizers and 
anticonvulsants was made by classifying medications (e.g., valproate and carbamazepine) 
as mood stabilizers for all individuals who did not have a diagnosis of seizure disorder, as 
was done by others (Esbensen et al. 2009; Lake et al. 2012). Medication use was 
determined according to medications used regularly on the date of survey completion. 
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Psychotropic polypharmacy was operationalized as the concurrent use of two or more 
psychotropic medications in the same individual, either within or between therapeutic 
classes.  
Data Analysis  
 Univariate statistics were used to describe demographic and medication 
information for the sample (numbers and percentages for count data and means and 
standard deviations for continuous variables). Bivariate analyses were used to analyze the 
association between individual child, parent, and service variables and ≥2 psychotropic 
medications (yes/no). Variables significantly associated with ≥2 psychotropic 
medications at or below p ≤ 0.05 were included in a multiple variable logistic regression.  
Odds ratios with 95% confidence intervals were reported.  Statistical analyses were 
conducted using SPSS version 20.0.   
 Results 
Participant Characteristics 
 The current study examined medication profiles and predictors of medication use 
among parents of 363 adolescents and young adults with ASD. Individuals with ASD 
were between 12 and 30 years of age with a mean age of 17.30 (SD = 4.01). The majority 
of these individuals lived with family (338; 93%), over three quarters were male, and 
most were Caucasian (Table 1). Approximately one quarter of the sample (100; 27.6%) 
had a diagnosis of autism, 31.2% (113) were diagnosed with Asperger Syndrome, and 
40.9%  (148) were diagnosed with pervasive developmental disorder not otherwise 
specified (PDD-NOS) or ASD.  
At the time of data collection, 182 of 363 (50.1%) adolescents and young adults 
were prescribed at least 1 psychotropic medication. See Table 2 for breakdown of 
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medication by class. The most commonly prescribed medication was antipsychotic 
medication, followed by antidepressant, and stimulant medications. Approximately one 
quarter (26.4%) of individuals were prescribed two or more psychotropic medications, 
and of those prescribed psychotropic medications, 13.2% were taking two or more 
psychotropic medications from the same therapeutic class (i.e., intraclass polypharmacy).  
Child, parent and service factors associated with polypharmacy 
Results of bivariate analyses for ≥ two psychotropic medications are presented in 
Table 3. Child clinical variables significantly related to psychotropic polypharmacy were: 
history of hurting others (p <0.001), history of self-injury (p=0.004), history of 
psychiatric admission (p <0.001) and having an additional psychiatric diagnosis other 
than an ASD (p <0.001). No child demographic (e.g., age, gender, intellectual disability) 
variables were related to psychotropic polypharmacy.  In terms of parent variables, 
family counseling (p=0.005), having an additional child with ASD (p=0.037), parent 
crisis (p=0.028), and parent burden (p=0.036), were significantly related to psychotropic 
polypharmacy. No parent demographic variables predicted polypharmacy. In terms of 
service use, only child therapy use (e.g., counseling, behaviour therapy) (p <0.001) was 
significantly positively related to polypharmacy. That said, just over one third (37%) of 
those taking two or more psychotropic medications were not receiving any therapy 
services.  
Prediction of polypharmacy: Multiple variable logistic regression analysis 
 
Results of the logistic regression are summarized in Table 4. In the adjusted 
analysis, history of hurting others, having an additional psychiatric diagnosis, parent 
burden, and therapy use were significant predictors of psychotropic polypharmacy. 
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Specifically, adolescents and young adults with ASD with a history of hurting others 
were 2.7 times more likely to be prescribed two or more psychotropic medications than 
those without a history of hurting others. Similarly, adolescents and young adults with an 
additional psychiatric diagnosis were 2.4 times more likely to receive psychotropic 
polypharmacy than those without an additional psychiatric diagnosis. In terms of parent 
variables, parents reporting high levels of burden were 2.5 times more likely to be 
prescribed two or more psychotropic medications than parents who did not report high 
levels of burden. Finally, in terms of service use, adolescents and young adults receiving 
therapy were 2.8 times more likely to be prescribed two or more psychotropic 
medications than those not receiving therapy. 
Discussion 
This is the first study of adolescents and young adults with ASD to examine both 
demographic and clinical variables associated with multiple psychotropic medication use, 
and to consider the relative influence of parent and service factors. One quarter of 
adolescents and young adults with ASD were taking two or more psychotropic 
medications, and 13% of individuals taking two or more psychotropic medications were 
also taking psychotropic medications from the same therapeutic class (e.g., two 
antipsychotic, mood stabilizer or anxiolytic medications), which, according to prescribing 
guidelines for individuals with developmental disabilities, should be avoided (Posey et al. 
2008; Reiss and Aman 1995; Sullivan et al. 2011). Psychotropic polypharmacy rates in 
this study, are similar to those observed in other clinical populations, including youth 
with symptoms of mania (Kowatch et al. 2013) and adults with schizophrenia or 
schizoaffective disorders (Goren et al. 2013). When all factors were considered, the main 
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contributors to psychotropic polypharmacy in the current study were history of hurting 
others, psychiatric comorbidity, parent burden and therapy service use.  This would 
suggest that psychotropic polypharmacy is not only associated with the child’s clinical 
presentation, but also with factors related to caregivers and service use.  
Child Variables 
In terms of child demographic variables, and contrary to what has been reported 
in previous studies (Coury et al. 2012; Esbensen et al. 2009; Logan et al. 2012; Memari et 
al. 2012; Spencer et al. 2013), age was not associated with psychotropic polypharmacy in 
the current study. There may be a few explanations for these differences with regard to 
age. Two of the aforementioned studies (Coury et al., 2012; Spencer et al., 2013) 
consisted of large samples, including young children of a broad age range. As a result, the 
power of these studies was greater and they may have been more likely to detect an age 
effect because of their inclusion of younger children. Our study consisted of fewer 
individuals and because we only studied individuals between the ages of 12 and 30, we 
may have experienced age-related attenuation. However, three other studies, two of 
adolescents (Logan et al. 2012; Memari et al. 2012), and one of adolescents and adults 
(Esbensen et al., 2009), did report an association between age and polypharmacy, and 
their sample sizes were similar to ours. A lack of association between gender and 
polypharmacy is consistent with findings among children and adolescents with ASD 
(Coury et al. 2012; Memari et al., 2012; Spencer et al. 2013). No other studies considered 
the association between polypharmacy and autism diagnosis, and only one other study 
considered the association between polypharmacy and ID (Spencer et al., 2013). 
Consistent with findings of the current study, Spencer and colleagues (2013) did not 
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report an association between ID and polypharmacy. The finding of no association 
between psychotropic polypharmacy and autism diagnosis or intellectual disability 
supports the notion that polypharmacy is an issue for adolescents and young adults with 
ASD across levels of cognitive functioning and autism severity, and is not a concern 
unique to lower functioning individuals. While the reasons for prescribing multiple 
psychotropic medications and the ways in which they are monitored may differ among 
these individuals, polypharmacy can be a concern across the spectrum.  
Two clinical variables were associated with psychotropic polypharmacy in the 
multivariate analyses: history of hurting others and presence of an additional psychiatric 
diagnosis. One would expect that individuals with comorbid mental health problems 
would be more likely to be prescribed multiple medications than those without. This 
finding was also observed in a study of children with ASD, where children with co-
occurring conditions had higher odds of polypharmacy (Spencer et al. 2013). The finding 
that hurting others was associated with psychotropic polypharmacy is consistent with our 
previous work with an adult sample, the majority of whom were no longer living with 
family (Lake et al. 2012), although there is no systematic evidence to indicate that 
multiple psychotropic medications, particularly medications from the same class, are 
more effective than one psychotropic medication in addressing aggressive behaviour. It 
would be important to examine whether parents think that multiple psychotropic 
medications are in fact working, since some of these medications both individually or 
taken together, can have adverse or paradoxical side effects, and in some cases, may 
worsen the behaviours they are prescribed to treat (Bradley and Lofchy 2005; Myers 
2007).  
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Parent Variables 
Parent crisis, parent burden, and the use of family counseling services were all 
associated with psychotropic polypharmacy at the bivariate level, and parent burden 
remained a significant predictor after adjusting for clinical and service factors. This 
means that even when controlling for severity of autism symptoms, presence of ID, and 
child behaviour or mental health problems, parents’ perception of their difficulty caring 
for their child was still an important predictor of polypharmacy. The relationship between 
parent burden and increased psychotropic medication use may be influenced by a third 
mediating variable (e.g., aggressive behaviour). For example, when faced with aggressive 
behaviour, parents may have a greater sense of burden and be more likely to use multiple 
medications. It is well known that parents report greater distress in the presence of child 
behaviour and mental health problems (Cadman et al. 2012; Kring et al. 2008; Lin 2011; 
Schieve et al. 2007), and that mental health problems are associated with greater 
medication use. It remains an intriguing possibility that parent burden may influence the 
decision to medicate, but more refined measures of aggressive behaviour, behaviours 
targeted with medication, and the decision to medicate are required to better understand 
the inter-relationships between these child and parent variables. Whatever the reason, 
parent burden was elevated for parents’ who had a child using multiple medications, 
suggesting that supporting parents in these circumstances may be an important target for 
treatment and education.   
Service Variables 
 Among service variables, only therapy use predicted psychotropic polypharmacy. 
This finding suggests that the majority of adolescents and young adults prescribed 
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multiple psychotropic medications are doing so while accessing and receiving adjunct 
therapy services and supports (e.g., behaviour therapy, counseling). These results are 
similar to what has been found among the general youth population, where 68% of youth 
prescribed psychotropic medication also receive concurrent therapy (Harris et al. 2012). 
While it is positive that pharmacological treatments are not being used in lieu of non-
pharmacological treatments for the majority of individuals, just over one third (36%) of 
those taking two or more psychotropic medications, were not receiving any additional 
therapy. This is particularly concerning given our knowledge that behaviour therapy in 
addition to psychiatric treatment is more effective than psychiatric treatment alone 
(Aman et al. 2009; Hassiotis et al. 2009; Kaplan and McCracken 2012; Myers and 
Plauche-Johnson 2007; Frazier et al. 2010). Although there is a need for more 
methodologically rigorous studies examining the effectiveness of psychosocial 
interventions for the treatment of aggression among persons with ASD, a number of 
studies demonstrate its treatment effectiveness (Brosnan & Healy, 2011; Campbell, 2003; 
Foxx, 2008) 
This study is subject to a number of limitations. First, findings were based on parent 
report, and we did not have access to corroborating sources to validate diagnoses or 
medications. However, only individuals with an SCQ score at or above the recommended 
research cutoff (≥12) (Brooks & Benson 2013) were included in these analyses. It is 
possible that some individuals in this study would not meet full DSM-V criteria for ASD; 
however, previous studies suggest that parent-reported ASD diagnoses produce 
prevalence estimates comparable to population-based studies using validated medical 
records or diagnostic tools (CDC 2012; 2013; Kogan et al. 2009). While we recognize 
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that our sample may not be representative of all individuals with ASD, most individuals 
with ASD tend to reside with their parents well into adulthood (Howlin and Moss 2012), 
thus findings from parent report surveys have considerable value in understanding 
adolescents and adults with ASD. Similarly, despite its constraints, a number of studies 
have used similar survey-based methods to study this population (Blumberg et al. 2013; 
Mazurek et al. 2011; Montes and Halterman 2007), including the 2011-2012 National 
Survey of Children’s Health (CDC 2013) and the 2011-2012 National Health Interview 
Survey (CDC 2012). 
Second, our measure of hurting others was not refined enough to directly address 
whether hurting others was a precursor to medication prescribing. Third, data collection 
in the current study did not consider a medication overlap period, which may have 
resulted in an overestimate of psychotropic polypharmacy rates if on the date medications 
were recorded the individual was being weaned off one medication while another was 
being introduced (Chen et al. 2011). Fourth, it is challenging to tease apart the 
relationship between predictors and outcomes based on the cross-sectional nature of the 
data in the current study. More refined study of these constructs and longitudinal data are 
needed.  
Conclusions 
Despite these limitations, findings from the current study have a number of 
important implications. Our results contribute to the literature on psychotropic 
medication use in adolescents and young adults with ASD, and confirm that this 
subgroup is a highly medicated population. Findings also suggest that the factors 
associated with psychotropic polypharmacy are complex and multifaceted. It may not 
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simply be the clinical variables related to the child which lead to multiple psychotropic 
medication use, but rather the interplay between child, parent, and service factors. While 
there are many circumstances where polypharmacy is a necessary and appropriate sign of 
good psychiatric care, identification of risk factors for psychotropic polypharmacy could 
inform the development of alternative interventions that complement or replace 
pharmacological treatments. This may include patient-centered supports for adolescents 
or young adults with ASD who present with comorbid mental health problems or a 
history of hurting others, as well as supports for parents of these individuals. Going 
forward, it will be important to study whether psychotropic medications are having their 
intended benefit among individuals with ASD and how these medications impact parent 
burden over time. There is also a need for an in-depth understanding of the choice to 
medicate from the perspective of parents and prescribing healthcare providers, as well as 
how these different factors come into play throughout the decision-making process. 
Findings from this study highlight the need to find ways to support parents who have 
children using multiple psychotropic medications whom appear to be highly burdened.  
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Clinical Significance: This is the first study of adolescents and young adults with ASD 
to examine both demographic and clinical variables associated with multiple 
psychotropic medication use, and to consider the relative influence of parent and service 
factors. Findings suggest that the factors associated with psychotropic polypharmacy are 
complex and multifaceted. In our study, it is not simply the clinical variables related to 
the child which lead to multiple psychotropic medication use, but rather the interplay 
between child, parent, and service factors. Clinically, identification of risk factors for 
psychotropic polypharmacy could inform the development of alternative interventions 
that complement pharmacological treatments. This may include patient-centered supports 
for adolescents or young adults with ASD who present with comorbid mental health 
problems or a history of hurting others, as well as supports for parents of these 
individuals. 
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